Evidence map›Paper›PMID 25337312›Full record

ArticleOman medical journal2014

Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman.

Jimmy Jose, Faisal Abdullah Ali Al-Tamimi, Manal Mahmoud Helal, Beena Jimmy, Qasim Al Riyami

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oman medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jimmy JoseAssistant Dean (Research) and Associate Professor, School of Pharmacy, College of Pharmacy and Nursing, University of Nizwa,P.B No 33, PO 616, Birkat Al Mouz, Nizwa, Sultanate of Oman.
Faisal Abdullah Ali Al-TamimiSenior Consultant, Physician & Rheumatologist, Department of Medicine, Nizwa Hospital, Ministry of Health, Sultanate of Oman.
Manal Mahmoud HelalSenior Specialist, Department of Medicine, Nizwa Hospital, Ministry of Health, Sultanate of Oman, and Associate Professor, General Medicine, Cairo University, Egypt.
Beena JimmyLecturer, School of Pharmacy, College of Pharmacy and Nursing, University of Nizwa, Nizwa, Sultanate of Oman.
Qasim Al RiyamiAssistant Dean (Training) School of Pharmacy, College of Pharmacy and Nursing, University of Nizwa, Nizwa, Sultanate of Oman.
University of Nizwa · OMMinistry of Health · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed at evaluating the prevalence, pattern and predisposing factors for hepatic adverse effects with statins in a regional hospital in Sultanate of Oman.

methodsA retrospective review of the patient files in Department of Medicine during the year 2011 was done to evaluate any hepatic dysfunction possibly related to statins among the patients. For each case of suspected statin induced hepatic effect, additional details on temporal relationship, pattern of presentation, management, final outcome and any contributing factors were obtained. Difference in the occurrence of hepatic effects based on the patient demographics and drug characteristics was additionally evaluated.

resultsA total of 927 patients meeting the inclusion criteria were included for the study. Mean age of the evaluated patients was 63.1 ± 11.37 and median duration of use of statin in months was 22 (IQR, 43.25). In 40 (4%) of the 927 patients, there was presence of a hepatic effect considered to be statin related and only in 12 (1%) patients a significant transaminase rise (>3 times) was observed. Median duration of use of statin among those patients who developed suspected statin induced hepatic effects and those who did not was 45 (IQR,52) and 21 (IQR, 43) months, respectively and the difference observed was statistically significant. A significant difference in the prevalence of hepatic effects was observed only based on the duration of statin use.

conclusionThere was an infrequent occurrence of significant hepatic effects associated with statins in the study population. Our results support the latest recommendations including from United States Federal Drug Administration (US FDA) that statins appear to be associated with a very low risk of serious liver injury and that routine periodic monitoring of transaminases does not appear to detect or prevent serious liver injury in association with statins.

Indexed as

hepatic effectsretrospective reviewstatinsSultanate of Oman

Identifiers

PMID25337312
PMCPMC4202230
OpenAlexW2104247612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.